SOUTH
SAN FRANCISCO, Calif., April 27,
2023 /PRNewswire/ -- IDEAYA Biosciences,
Inc. (Nasdaq:IDYA) today announced the closing of its
underwritten public offering of 8,858,121 shares of its common
stock at a public offering price of $18.50 per share, before underwriting discounts
and commissions, and pre-funded warrants to purchase 2,020,270
shares of common stock at a public offering price of $18.4999 per pre-funded warrant, before
underwriting discounts and commissions. This includes the exercise
in full by the underwriters of their option to purchase up to an
additional 1,418,920 shares of common stock in the offering. The
gross proceeds from the offering, before deducting underwriting
discounts and commissions and other offering expenses payable by
IDEAYA, were approximately $201 million.
J.P. Morgan, Jefferies, and Citigroup acted as joint
book-running managers for the offering. RBC Capital Markets and
Oppenheimer & Co. acted as lead managers for the offering.
The public offering was made by IDEAYA pursuant to a shelf
registration statement on Form S-3 that was previously filed with
and declared effective by the U.S. Securities and Exchange
Commission, or the SEC. The offering was made only by means of
a written prospectus and prospectus supplement that form a part of
the registration statement. A final prospectus supplement and
accompanying prospectus relating to the offering has been filed
with the SEC and is available on the SEC's website
at http://www.sec.gov. Copies of the final prospectus
supplement and the accompanying prospectus relating to the offering
may also be obtained by request from: J.P. Morgan, by mail at J.P.
Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY
11717, or by telephone at 866-803-9204, or by email at
prospectus-eq_fi@jpmorganchase.com; Jefferies, by mail at Jefferies
LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, New York, NY 10022, or by
telephone at 877-547-6340 or 877-821-7388, or by email at
Prospectus_Department@Jefferies.com; Citigroup, by mail at
Citigroup Global Markets Inc., c/o Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood,
NY 11717, or by telephone at 1-800-831-9146; RBC Capital
Markets, LLC, Attention: Equity Capital Markets, 200 Vesey Street,
8th Floor, New York, New York
10281, by telephone at (877) 822-4089 or by email at
equityprospectus@rbccm.com; or Oppenheimer & Co. Inc.,
Attention: Syndicate Prospectus Department, 85 Broad Street, 26th
Floor, New York, NY 10004, by
telephone at 212-667-8055, or by email at
EquityProspectus@opco.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed
to the discovery and development of targeted therapeutics for
patient populations selected using molecular
diagnostics. IDEAYA's approach integrates capabilities in
identifying and validating translational biomarkers with drug
discovery to select patient populations most likely to benefit from
its targeted therapies. IDEAYA is applying its research
and drug discovery capabilities to synthetic lethality – which
represents an emerging class of precision medicine
targets.
Investor and Media Contact
IDEAYA Biosciences
Paul Stone
Chief Financial Officer
investor@ideayabio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-announces-closing-of-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares-301809939.html
SOURCE IDEAYA Biosciences, Inc.